Treatment of Coronavirus COVID-19 Pneumonia (Pathogen SARS-CoV-2) With Cryopreserved Allogeneic P_MMSCs and UC-MMSCs

• Status: Recruiting
• Trial end date: 2021-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Assessment of the clinical effects of infusions of cryopreserved allogeneic multipotent mesenchymal stem cells of the placenta and umbilical cord for COVID-19 patients with acute respiratory distress syndrome.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Institute of Cell Therapy
• Collaborator: Kyiv City Clinical Hospital # 4
• Treatments: Anti-Bacterial Agents; Anticoagulants; Azithromycin; Ceftriaxone; Dexamethasone; Enoxaparin; Hormones

Criteria

Inclusion Criteria:

• Male or female, aged at 18 years (including) - 75 years old.

• Laboratory confirmation of SARS-CoV-2 infection by reverse-transcription polymerase chain reaction (RT-PCR) from any diagnostic sampling source.

• Pneumonia that is judged by X-ray imaging.

In accordance with any one of the following:

• dyspnea (RR ≥ 30 times / min);

• finger oxygen saturation ≤ 93% in resting state;

• arterial oxygen partial pressure (PaO2) / oxygen absorption concentration (FiO2) ≤ 300MMHG (if possible);

• invasive ventilation< 48 h.

Exclusion Criteria:

• Male or female, aged at <18 years and > 75 years old.

• Pregnancy, lactation and those who are not pregnant but do not take effective contraceptives measures.

• Patients with malignant tumor, other serious systemic diseases and psychosis.

• Patients who are participating in other clinical trials.

• Inability to provide informed consent or to comply with test requirements.

• Co-Infection of HIV, syphilis.

• Invasive ventilation > 48 h.

• Combined with other organ failure (need organ support).